Maravai LifeSciences (MRVI) Misses Q1 EPS by 1c, provides guidance

Maravai LifeSciences (NASDAQ: MRVI) reported Q1 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $46.9 million versus the consensus estimate of $45.6 million.

GUIDANCE:

Maravai LifeSciences sees FY2025 revenue of $185-205 million, versus the consensus of $192.7 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Traws Pharma (TRAW) Tops Q2 EPS by 27c
• BTIG Starts ADT (ADT) at Neutral
• Trump: Iran cannot have, in any way, shape, or form, a nuclear weapon